RP-L102
Phase 2Active 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fanconi Anemia Complementation Group A
Conditions
Fanconi Anemia Complementation Group A
Trial Timeline
Jul 15, 2020 → May 5, 2026
NCT ID
NCT04248439About RP-L102
RP-L102 is a phase 2 stage product being developed by Rocket Pharmaceuticals for Fanconi Anemia Complementation Group A. The current trial status is active. This product is registered under clinical trial identifier NCT04248439. Target conditions include Fanconi Anemia Complementation Group A.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04248439 | Phase 2 | Active |
| NCT04069533 | Phase 2 | Active |
| NCT03814408 | Phase 1 | UNKNOWN |
Competing Products
4 competing products in Fanconi Anemia Complementation Group A
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Etanercept | Amgen | Phase 1 | 32 |
| RP-L102 | Rocket Pharmaceuticals | Phase 1 | 25 |
| RP-L102 | Rocket Pharmaceuticals | Phase 2 | 44 |
| Busulfan + Fludarabine + Cyclophosphamide + Anti-Thymocyte Globulin (Rabbit) + G-CSF | Brain Biotech | Phase 2 | 44 |